Management of recurrent or metastatic thyroid cancer

Area of Science:

• Oncology
• Pharmacology
• Translational Medicine

Background:

• Vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitors (TKIs) are approved for recurrent or metastatic thyroid cancer.
• Clinical use of VEGFR-TKIs is challenged by significant toxicity, leading to treatment delays and a 'watch-and-wait' approach.
• Delayed VEGFR-TKI initiation can result in more severe adverse events and negative impacts on quality of life and patient outcomes.

Purpose of the Study:

• To discuss the clinical challenges associated with VEGFR-targeted TKI therapy in thyroid cancer.
• To highlight the demerits of the 'watch-and-wait' strategy.
• To emphasize the need for optimal timing, toxicity management, and future directions in precision medicine.

Main Methods:

• Review of current clinical practices and challenges in VEGFR-TKI therapy.
• Analysis of the implications of delayed treatment initiation.
• Discussion of supportive care, infrastructure, and patient education requirements.
• Exploration of future treatment paradigms, including molecular testing and precision medicine.

Main Results:

• Significant toxicity of VEGFR-TKIs often leads physicians to delay treatment.
• The 'watch-and-wait' approach exacerbates disease progression and negatively impacts quality of life, particularly in older patients or those with follicular thyroid cancer.
• Effective management of VEGFR-TKI toxicities necessitates robust supportive care, outpatient infrastructure, and patient education.

Conclusions:

• Optimal timing for initiating VEGFR-targeted TKI therapy in thyroid cancer requires careful consideration.
• Addressing VEGFR-TKI toxicities is paramount for successful treatment and requires comprehensive management strategies.
• Future advancements in thyroid cancer treatment will likely involve precision medicine, driven by molecular testing and translational research.